MiMedx Group
MDXGMiMedx is a biotechnology leader specializing in the development and commercialization of placental biologics and advanced healing solutions.
Earnings
Next report
Nov 4, 2026 (in 2 months)Segments
By product
Competitors
By market cap
By revenue growth
Profile
MiMedx is a biotechnology leader specializing in the development and commercialization of placental biologics and advanced healing solutions. The company leverages proprietary processing technology to provide a portfolio of human-derived, animal-derived, and synthetic tissues designed to treat chronic wounds, burns, and surgical complications. Their core value proposition centers on reducing healthcare costs and improving patient outcomes through clinically-proven regenerative medicine.
A pioneer in placental biologics with a leading market position in amniotic tissue allografts and a first-mover advantage in the Japanese market.
FAQ
- What is MiMedx Group's market cap?
- MiMedx Group (MDXG) has a market capitalization of $690.3M and trades on NASDAQ.
- What is MiMedx Group's revenue and profitability?
- MiMedx Group generated $355.2M in trailing twelve-month revenue with net income of $6.2M, representing a net margin of 1.8%. Gross margin stands at 78.8%, with free cash flow of $44.5M. The latest reported period is Q2 2026.
- Who are MiMedx Group's competitors?
- MiMedx Group's key competitors include Organogenesis Holdings Inc., Integra LifeSciences, Solventum Corporation, and others. These companies compete in similar markets and product categories.
- Who does MiMedx Group partner with?
- MiMedx Group's notable partners include Regenity Biosciences.
- Where is MiMedx Group headquartered?
- MiMedx Group is headquartered in United States of America and employs approximately 895 people. It has been publicly traded since 2007.
